Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...4243444546474849505152...123124»
  • ||||||||||  Review, Journal:  Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations. (Pubmed Central) -  Dec 7, 2022   
    As immunotherapy makes its way into the therapeutic landscape of HCC, other novel targeted therapies, such as lenvatinib, cabozantinib, ramucirumab, and regorafenib, have also been approved by regulatory authorities for treatment of advanced, unresectable HCC. This review article focuses on the first-line systemic treatment options for HCC while addressing some of the most important questions aimed at optimization of HCC treatment.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Journal:  Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors? (Pubmed Central) -  Dec 7, 2022   
    The therapeutic armamentarium has recently expanded following the approval of atezolizumab plus bevacizumab...The biological heterogeneity highlighted in HCC patients, along with the growing number of therapeutic options, makes the identification of stratification tools able to define which patients are more likely to respond to a treatment rather than another one of crucial interest. Further investigation deepening the biological pathways underlying HCC carcinogenesis are of particular interest in order to pave the way for precision medicine even for HCC patients.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Targeting the FGF/FGFR axis and its co-alteration allies. (Pubmed Central) -  Dec 2, 2022   
    FGF/FGFR alterations portend a poor prognosis and are frequently accompanied by pathogenic co-aberrations. Malignancies harboring co-alterations that activate both cyclin and FGFR pathways can be co-targeted by CDK4/6 and FGFR inhibitors.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal:  Targeted Therapies in the Treatment of Uterine Serous Carcinoma. (Pubmed Central) -  Nov 30, 2022   
    Treatment with pembrolizumab and lenvatinib suggests a 50% response rate in women with recurrent disease which serves as a promising targeted treatment strategy...Several trials evaluating these targeted agents are ongoing, and those results are eagerly awaited. As such, enrollment of patients in clinical trials is highly recommended as it will provide patients with a higher level of personalized cancer care.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Review, Journal:  Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Nov 27, 2022   
    Lenvatinib showed a significantly superior efficacy compared with sorafenib (HR for OS, 0.85 and HR for PFS, 0.72; OR for ORR, 4.25 and OR for DCR, 2.23). The current study demonstrates that lenvatinib can provide better tumor responses and survival benefits than sorafenib as a first-line treatment for unresectable HCC, with a comparable incidence of adverse events.
  • ||||||||||  Review, Journal:  Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. (Pubmed Central) -  Nov 27, 2022   
    Osteosarcoma (OS) is the most frequent primary bone tumor and several TKIs have demonstrated clinical benefit in phase II clinical trials (cabozantinib, regorafenib, apatinib, sorafenib, and lenvatinib)...Previous reviews have mainly provided information on TKIs for OS and ES. We aim to summarize the existing knowledge regarding the use of TKIs in all bone sarcomas including the most recent studies as well as the potential synergistic effects of their combination with other systemic therapies.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Review, Journal:  Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma. (Pubmed Central) -  Nov 27, 2022   
    Accumulating evidence from encouraging in vitro and in vivo animal models has demonstrated that ITCs have multiple biological activities, especially their potentially health-promoting activities (antibacterial, antioxidant, and anticarcinogenic effects). In this review, we aim to comprehensively summarize the chemopreventive, anticancer, and chemosensitizative effects of ITCs on HCC, and explain the underlying molecular mechanisms.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial completion date, Trial primary completion date, Tumor mutational burden, IO biomarker, Metastases:  JS001-027-III-HCC: Phase III Study of Toripalimab?JS001? Combined With Lenvatinib for Advanced HCC (clinicaltrials.gov) -  Nov 23, 2022   
    P3,  N=519, Recruiting, 
    We discuss the unsatisfactory search for suitable biomarkers and key ongoing trials in this field. Trial completion date: Jan 2025 --> Sep 2026 | Trial primary completion date: Aug 2023 --> May 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion, Trial completion date, Trial primary completion date:  A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) -  Nov 22, 2022   
    P1b,  N=30, Completed, 
    Rechallenge TACE after LEN is an effective treatment that may result in a favorable prognosis. Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Oct 2022 | Trial primary completion date: Jun 2023 --> Oct 2022
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
    Review, Journal:  Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. (Pubmed Central) -  Nov 19, 2022   
    Previously approved agents for first-line therapy, such as sorafenib, lenvatinib and bevacizumab combined with atezolizumab, have focused on angiogenesis. HIMALAYA was the first trial to demonstrate the benefit of dual immune checkpoint inhibitors, representing a new treatment option in this scenario.
  • ||||||||||  Clinical guideline:  French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. (Pubmed Central) -  Nov 19, 2022   
    HIMALAYA was the first trial to demonstrate the benefit of dual immune checkpoint inhibitors, representing a new treatment option in this scenario. These updated recommendations are a reference that will allow French and French-speaking practitioners to improve kidney cancer management.
  • ||||||||||  The role of cytoreductive nephrectomy in the era of immune-combination therapies: A meta-analysis () -  Nov 18, 2022 - Abstract #EMUC2022EMUC_267;    
    ICI-combination therapy was associated with significantly better OS/PFS than sunitinib in patients who had undergone CN (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.59–0.77/HR, 0.57; 95% CI, 0.44–0.74, respectively; both P<0.001), and in those who had not (HR, 0.69; 95% CI, 0.57–0.85/ HR, 0.63; 95% CI, 0.52–0.77, respectively; both P<0.001)...In network meta-analyses, nivolumab plus cabozantinib was the most effective regimen in those undergoing CN, and pembrolizumab plus lenvatinib for those not undergoing CN...Careful patient selection remains paramount. As each ICI-combination regimen varied widely in its effect in those who had and had not undergone CN, CN may contribute to better treatment decision-making for ICI-combination therapy recipients.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Journal:  Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. (Pubmed Central) -  Nov 18, 2022   
    No statistical differences were found in all efficacy endpoints at the cutoff age of 65 years. For patients aged ≥75 years, application of PD-1 inhibitors in combination with sorafenib or lenvatinib is promising, but this has to be done with caution and needs to be confirmed by future prospective studies.